메뉴 건너뛰기




Volumn 7, Issue 1, 2011, Pages 16-24

Updates in the management of hepatocellular carcinoma

Author keywords

Cancer screening and surveillance; Chemoembolization; Liver cancer staging; Locoregional therapy; Radiofrequency ablation; Sorafenib; Yttrium 90

Indexed keywords

ALPHA FETOPROTEIN; BEVACIZUMAB; DOXORUBICIN; ERLOTINIB; LIVER ENZYME; POLYVINYL ALCOHOL; SORAFENIB; STARCH MICROSPHERE; VIRUS DNA; YTTRIUM 90;

EID: 79951800609     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (86)

References (106)
  • 1
    • 79951791027 scopus 로고    scopus 로고
    • AASLD Practice Guideline. Management of hepatocellular carcinoma: An update
    • Bruix J, Sherman M. AASLD Practice Guideline. Management of hepatocellular carcinoma: an update. Hepatology. 2010;1-35. http://www.aasld. org/practiceguidelines/Documents/Bookmarked%20practice%20Guidelines/ Hccupdate2010.pdf.
    • (2010) Hepatology , pp. 1-35
    • Bruix, J.1    Sherman, M.2
  • 4
    • 63049133092 scopus 로고    scopus 로고
    • Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005
    • Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-1491.
    • (2009) J Clin Oncol , vol.27 , pp. 1485-1491
    • Altekruse, S.F.1    McGlynn, K.A.2    Reichman, M.E.3
  • 5
    • 77951781372 scopus 로고    scopus 로고
    • A multidisciplinary approach to the management of hepatocellular carcinoma
    • Gish RG, Marrero JA, Benson AB. A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2010;6 (supp 7):1-14.
    • (2010) Gastroenterol Hepatol (N Y) , vol.6 , Issue.SUPPL. 7 , pp. 1-14
    • Gish, R.G.1    Marrero, J.A.2    Benson, A.B.3
  • 7
    • 77950553502 scopus 로고    scopus 로고
    • Diagnosis and management of hepatocellular carcinoma: Results of a consensus meeting of the Ottawa Hospital Cancer Centre
    • Asmis T, Balaa F, Scully L, et al. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol. 2010;17:6-12.
    • (2010) Curr Oncol , vol.17 , pp. 6-12
    • Asmis, T.1    Balaa, F.2    Scully, L.3
  • 8
    • 33646567160 scopus 로고    scopus 로고
    • Systematic review: Evidence-based management of hepatocellular carcinoma - An updated analysis of randomized controlled trials
    • Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23:1535-1547.
    • (2006) Aliment Pharmacol Ther , vol.23 , pp. 1535-1547
    • Lopez, P.M.1    Villanueva, A.2    Llovet, J.M.3
  • 9
    • 0019451351 scopus 로고
    • Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan
    • Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2: 1129-1133.
    • (1981) Lancet , vol.2 , pp. 1129-1133
    • Beasley, R.P.1    Hwang, L.Y.2    Lin, C.C.3    Chien, C.S.4
  • 10
    • 0024241542 scopus 로고
    • Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: A prospective study
    • Sakuma K, Saitoh N, Kasai M, et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology. 1988;8:1642-1646.
    • (1988) Hepatology , vol.8 , pp. 1642-1646
    • Sakuma, K.1    Saitoh, N.2    Kasai, M.3
  • 11
    • 0036614299 scopus 로고    scopus 로고
    • Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
    • Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002; 35:1522-1527.
    • (2002) Hepatology , vol.35 , pp. 1522-1527
    • Hsu, Y.S.1    Chien, R.N.2    Yeh, C.T.3
  • 12
    • 77951282725 scopus 로고    scopus 로고
    • Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States
    • Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132-141.
    • (2010) Hepatology , vol.52 , pp. 132-141
    • Davila, J.A.1    Morgan, R.O.2    Richardson, P.A.3    Du, X.L.4    McGlynn, K.A.5    El-Serag, H.B.6
  • 13
    • 33847701354 scopus 로고    scopus 로고
    • Chronic hepatitis B
    • Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539.
    • (2007) Hepatology , vol.45 , pp. 507-539
    • Lok, A.S.1    McMahon, B.J.2
  • 14
    • 84984555343 scopus 로고    scopus 로고
    • Hepatitis B e antigen and the risk of hepatocellular carcinoma
    • Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168-174.
    • (2002) N Engl J Med , vol.347 , pp. 168-174
    • Yang, H.I.1    Lu, S.N.2    Liaw, Y.F.3
  • 15
    • 0036120412 scopus 로고    scopus 로고
    • Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences
    • Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002;11:369-376.
    • (2002) Cancer Epidemiol Biomarkers Prev , vol.11 , pp. 369-376
    • Evans, A.A.1    Chen, G.2    Ross, E.A.3    Shen, F.M.4    Lin, W.Y.5    London, W.T.6
  • 16
    • 0031837430 scopus 로고    scopus 로고
    • Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis
    • Huo TI, Wu JC, Lee PC, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology. 1998;28:231-236.
    • (1998) Hepatology , vol.28 , pp. 231-236
    • Huo, T.I.1    Wu, J.C.2    Lee, P.C.3
  • 17
    • 0030696048 scopus 로고    scopus 로고
    • Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa
    • European Concerted Action on Viral Hepatitis (EUROHEP)
    • Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 1997;26:1338-1342.
    • (1997) Hepatology , vol.26 , pp. 1338-1342
    • Fattovich, G.1    Giustina, G.2    Realdi, G.3    Corrocher, R.4    Schalm, S.W.5
  • 18
    • 0001731999 scopus 로고    scopus 로고
    • Delayed clearance of serum HBsAg in compensated cirrhosis B: Relation to interferon alpha therapy and disease prognosis
    • European Concerted Action on Viral Hepatitis (EUROHEP)
    • Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol. 1998;93:896-900.
    • (1998) Am J Gastroenterol , vol.93 , pp. 896-900
    • Fattovich, G.1    Giustina, G.2    Sanchez-Tapias, J.3
  • 19
    • 29944436855 scopus 로고    scopus 로고
    • Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    • REVEAL-HBV Study Group
    • Chen CJ, Yang HI, Su J, et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
    • (2006) JAMA , vol.295 , pp. 65-73
    • Chen, C.J.1    Yang, H.I.2    Su, J.3
  • 20
    • 77952711598 scopus 로고    scopus 로고
    • Diagnosis and management of autoimmune hepatitis
    • Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-2223.
    • (2010) Hepatology , vol.51 , pp. 2193-2223
    • Manns, M.P.1    Czaja, A.J.2    Gorham, J.D.3
  • 21
    • 0035056663 scopus 로고    scopus 로고
    • Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status
    • Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570-575.
    • (2001) J Hepatol , vol.34 , pp. 570-575
    • Trevisani, F.1    D'Intino, P.E.2    Morselli-Labate, A.M.3
  • 22
    • 75449103932 scopus 로고    scopus 로고
    • Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma
    • HALT-C Trial Group
    • Lok AS, Sterling RK, Everhart JE, et al; HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493-502.
    • (2010) Gastroenterology , vol.138 , pp. 493-502
    • Lok, A.S.1    Sterling, R.K.2    Everhart, J.E.3
  • 23
    • 0029099151 scopus 로고
    • A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients
    • Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology. 1995;22:802-807.
    • (1995) Hepatology , vol.22 , pp. 802-807
    • Shiraki, K.1    Takase, K.2    Tameda, Y.3    Hamada, M.4    Kosaka, Y.5    Nakano, T.6
  • 24
    • 0032951103 scopus 로고    scopus 로고
    • Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: Special reference to imaging diagnosis
    • Kumada T, Nakano S, Takeda I, et al. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol 1999;30:125-130.
    • (1999) J Hepatol , vol.30 , pp. 125-130
    • Kumada, T.1    Nakano, S.2    Takeda, I.3
  • 25
    • 0033071014 scopus 로고    scopus 로고
    • Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein
    • Okuda K, Tanaka M, Kanazawa N, et al. Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein. Int J Oncol. 1999;14:265-271.
    • (1999) Int J Oncol , vol.14 , pp. 265-271
    • Okuda, K.1    Tanaka, M.2    Kanazawa, N.3
  • 26
    • 0032822689 scopus 로고    scopus 로고
    • Usefulness of measurement of Lens culinaris agglutininreactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma
    • Hayashi K, Kumada T, Nakano S, et al. Usefulness of measurement of Lens culinaris agglutininreactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3028-3033.
    • (1999) Am J Gastroenterol , vol.94 , pp. 3028-3033
    • Hayashi, K.1    Kumada, T.2    Nakano, S.3
  • 27
    • 78649296731 scopus 로고    scopus 로고
    • Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma
    • Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci. 2010;55: 3576-3583.
    • (2010) Dig Dis Sci , vol.55 , pp. 3576-3583
    • Tamura, Y.1    Igarashi, M.2    Kawai, H.3    Suda, T.4    Satomura, S.5    Aoyagi, Y.6
  • 28
    • 34848886470 scopus 로고    scopus 로고
    • Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis
    • Sterling RK, Jeffers L, Gordon F, et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol. 2007;102:2196-2205.
    • (2007) Am J Gastroenterol , vol.102 , pp. 2196-2205
    • Sterling, R.K.1    Jeffers, L.2    Gordon, F.3
  • 29
    • 34447260276 scopus 로고    scopus 로고
    • Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: A comparison of AFP, DCP, and AFP-L3
    • Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007;3:79-87.
    • (2007) Cancer Biomark , vol.3 , pp. 79-87
    • Volk, M.L.1    Hernandez, J.C.2    Su, G.L.3    Lok, A.S.4    Marrero, J.A.5
  • 30
    • 67649305155 scopus 로고    scopus 로고
    • Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma
    • Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110-118.
    • (2009) Gastroenterology , vol.137 , pp. 110-118
    • Marrero, J.A.1    Feng, Z.2    Wang, Y.3
  • 31
    • 0027154890 scopus 로고
    • Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein
    • Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 1993;328:1802-1806.
    • (1993) N Engl J Med , vol.328 , pp. 1802-1806
    • Sato, Y.1    Nakata, K.2    Kato, Y.3
  • 32
    • 0035128185 scopus 로고    scopus 로고
    • Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis
    • Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251-259.
    • (2001) Gut , vol.48 , pp. 251-259
    • Bolondi, L.1    Sofia, S.2    Siringo, S.3
  • 33
    • 0021265949 scopus 로고
    • Prognostic value of Child-Turcotte criteria in medically treated cirrhosis
    • Christensen E, Schlichting P, Fauerholdt L, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology. 1984;4:430-435.
    • (1984) Hepatology , vol.4 , pp. 430-435
    • Christensen, E.1    Schlichting, P.2    Fauerholdt, L.3
  • 34
    • 0037223652 scopus 로고    scopus 로고
    • Model for end-stage liver disease (MELD) and allocation of donor livers
    • Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96.
    • (2003) Gastroenterology , vol.124 , pp. 91-96
    • Wiesner, R.1    Edwards, E.2    Freeman, R.3
  • 35
    • 33745367765 scopus 로고    scopus 로고
    • Liver transplantation with the MELD system: A prospective study from a single European center
    • Ravaioli M, Grazi GL, Ballardini G, et al. Liver transplantation with the MELD system: a prospective study from a single European center. Am J Transplant. 2006;6:1572-1577.
    • (2006) Am J Transplant , vol.6 , pp. 1572-1577
    • Ravaioli, M.1    Grazi, G.L.2    Ballardini, G.3
  • 36
    • 0033817471 scopus 로고    scopus 로고
    • Liver transplant waiting time does not correlate with waiting list mortality: Implications for liver allocation policy
    • Freeman RB Jr, Edwards EB. Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy. Liver Transpl. 2000;6:543-552.
    • (2000) Liver Transpl , vol.6 , pp. 543-552
    • Freeman Jr., R.B.1    Edwards, E.B.2
  • 38
    • 0032473697 scopus 로고    scopus 로고
    • Final rule with comment period
    • Organ Procurement and Transplantation Network - HRSA
    • Organ Procurement and Transplantation Network - HRSA. Final rule with comment period. Fed Regist. 1998;63:16296.
    • (1998) Fed Regist , vol.63 , pp. 16296
  • 39
    • 0036714685 scopus 로고    scopus 로고
    • The new liver allocation system: Moving toward evidence-based transplantation policy
    • Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8: 851-858.
    • (2002) Liver Transpl , vol.8 , pp. 851-858
    • Freeman Jr., R.B.1    Wiesner, R.H.2    Harper, A.3
  • 41
    • 0037087696 scopus 로고    scopus 로고
    • Simplified staging for hepatocellular carcinoma
    • Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20:1527-1536.
    • (2002) J Clin Oncol , vol.20 , pp. 1527-1536
    • Vauthey, J.N.1    Lauwers, G.Y.2    Esnaola, N.F.3
  • 43
    • 0021965806 scopus 로고
    • Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients
    • Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918-928.
    • (1985) Cancer , vol.56 , pp. 918-928
    • Okuda, K.1    Ohtsuki, T.2    Obata, H.3
  • 44
    • 0034107047 scopus 로고    scopus 로고
    • Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma
    • The Cancer of the Liver Italian Program (CLIP) Investigators
    • The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31:840-845.
    • (2000) Hepatology , vol.31 , pp. 840-845
  • 45
    • 14544302673 scopus 로고    scopus 로고
    • Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: Comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre
    • Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005;54:411-418.
    • (2005) Gut , vol.54 , pp. 411-418
    • Grieco, A.1    Pompili, M.2    Caminiti, G.3
  • 46
    • 0032879468 scopus 로고    scopus 로고
    • Prognosis of hepatocellular carcinoma: The BCLC staging classification
    • Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
    • (1999) Semin Liver Dis , vol.19 , pp. 329-338
    • Llovet, J.M.1    Brú, C.2    Bruix, J.3
  • 47
    • 33644909117 scopus 로고    scopus 로고
    • Prospective validation of the Barcelona Clinic Liver Cancer staging system
    • Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44:723-731.
    • (2006) J Hepatol , vol.44 , pp. 723-731
    • Cillo, U.1    Vitale, A.2    Grigoletto, F.3
  • 48
    • 0033646209 scopus 로고    scopus 로고
    • Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan
    • The Liver Cancer Study Group of Japan
    • Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224-1229.
    • (2000) Hepatology , vol.32 , pp. 1224-1229
    • Arii, S.1    Yamaoka, Y.2    Futagawa, S.3
  • 49
    • 17344368270 scopus 로고    scopus 로고
    • Early hepatocellular carcinoma as an entity with a high rate of surgical cure
    • Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998;28:1241-1246.
    • (1998) Hepatology , vol.28 , pp. 1241-1246
    • Takayama, T.1    Makuuchi, M.2    Hirohashi, S.3
  • 50
    • 0032742183 scopus 로고    scopus 로고
    • Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation
    • Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-1440.
    • (1999) Hepatology , vol.30 , pp. 1434-1440
    • Llovet, J.M.1    Fuster, J.2    Bruix, J.3
  • 51
    • 0033498334 scopus 로고    scopus 로고
    • An analysis of 412 cases of hepatocellular carcinoma at a Western center
    • Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229:790-800.
    • (1999) Ann Surg , vol.229 , pp. 790-800
    • Fong, Y.1    Sun, R.L.2    Jarnagin, W.3    Blumgart, L.H.4
  • 52
    • 0034935195 scopus 로고    scopus 로고
    • Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value
    • Grazi GL, Ercolani G, Pierangeli F, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001;234:71-78.
    • (2001) Ann Surg , vol.234 , pp. 71-78
    • Grazi, G.L.1    Ercolani, G.2    Pierangeli, F.3
  • 53
    • 67649497434 scopus 로고    scopus 로고
    • Predictors of survival after resection of early hepatocellular carcinoma
    • Nathan H, Schulick RD, Choti MA, et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799-805.
    • (2009) Ann Surg , vol.249 , pp. 799-805
    • Nathan, H.1    Schulick, R.D.2    Choti, M.A.3
  • 54
    • 0034034029 scopus 로고    scopus 로고
    • Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal
    • Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg. 2000;231:544-551.
    • (2000) Ann Surg , vol.231 , pp. 544-551
    • Poon, R.T.1    Fan, S.T.2    Ng, I.O.3    Wong, J.4
  • 55
    • 20344367769 scopus 로고    scopus 로고
    • Resection and liver transplantation for hepatocellular carcinoma
    • Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181-200.
    • (2005) Semin Liver Dis , vol.25 , pp. 181-200
    • Llovet, J.M.1    Schwartz, M.2    Mazzaferro, V.3
  • 56
    • 0345299824 scopus 로고    scopus 로고
    • Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
    • Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
    • (1996) N Engl J Med , vol.334 , pp. 693-699
    • Mazzaferro, V.1    Regalia, E.2    Doci, R.3
  • 57
    • 0032877161 scopus 로고    scopus 로고
    • Liver transplantation for hepatocellular carcinoma
    • Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 1999;19:311-322.
    • (1999) Semin Liver Dis , vol.19 , pp. 311-322
    • Bismuth, H.1    Majno, P.E.2    Adam, R.3
  • 58
    • 0027532022 scopus 로고
    • Surgical treatment of hepatocellular carcinoma in cirrhosis: Liver resection or transplantation?
    • Bismuth H, Chiche L, Adam R, Castaing D. Surgical treatment of hepatocellular carcinoma in cirrhosis: liver resection or transplantation? Transplant Proc. 1993;25:1066-1067.
    • (1993) Transplant Proc , vol.25 , pp. 1066-1067
    • Bismuth, H.1    Chiche, L.2    Adam, R.3    Castaing, D.4
  • 59
    • 17344364935 scopus 로고    scopus 로고
    • Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power
    • Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology. 1998;27:1572-1577.
    • (1998) Hepatology , vol.27 , pp. 1572-1577
    • Llovet, J.M.1    Bruix, J.2    Fuster, J.3
  • 60
    • 0035028451 scopus 로고    scopus 로고
    • Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis
    • Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080-1086.
    • (2001) Hepatology , vol.33 , pp. 1080-1086
    • Jonas, S.1    Bechstein, W.O.2    Steinmuller, T.3
  • 61
    • 77749320254 scopus 로고    scopus 로고
    • Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States
    • Pomfret E, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl. 2010;16:262-278.
    • (2010) Liver Transpl , vol.16 , pp. 262-278
    • Pomfret, E.1    Washburn, K.2    Wald, C.3
  • 62
    • 57749191711 scopus 로고    scopus 로고
    • Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis
    • Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43.
    • (2009) Lancet Oncol , vol.10 , pp. 35-43
    • Mazzaferro, V.1    Llovet, J.M.2    Miceli, R.3
  • 63
    • 49649104491 scopus 로고    scopus 로고
    • Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma
    • Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2008;14:1107-1115.
    • (2008) Liver Transpl , vol.14 , pp. 1107-1115
    • Toso, C.1    Trotter, J.2    Wei, A.3
  • 64
    • 35248823540 scopus 로고    scopus 로고
    • Liver transplantation for hepatocellular carcinoma: Validation of the UCSF-expanded criteria based on preoperative imaging
    • Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7:2587-2596.
    • (2007) Am J Transplant , vol.7 , pp. 2587-2596
    • Yao, F.Y.1    Xiao, L.2    Bass, N.M.3    Kerlan, R.4    Ascher, N.L.5    Roberts, J.P.6
  • 65
    • 0036712001 scopus 로고    scopus 로고
    • Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria
    • Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8:765-774.
    • (2002) Liver Transpl , vol.8 , pp. 765-774
    • Yao, F.Y.1    Ferrell, L.2    Bass, N.M.3    Bacchetti, P.4    Ascher, N.L.5    Roberts, J.P.6
  • 66
    • 0034991518 scopus 로고    scopus 로고
    • Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival
    • Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-1403.
    • (2001) Hepatology , vol.33 , pp. 1394-1403
    • Yao, F.Y.1    Ferrell, L.2    Bass, N.M.3
  • 67
    • 35248823540 scopus 로고    scopus 로고
    • Liver transplantation for hepatocellular carcinoma: Validation of the UCSF expanded criteria based on pre-operative imaging
    • Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF expanded criteria based on pre-operative imaging. Am J Transpl. 2007;7:2587-2596.
    • (2007) Am J Transpl , vol.7 , pp. 2587-2596
    • Yao, F.Y.1    Xiao, L.2    Bass, N.M.3    Kerlan, R.4    Ascher, N.L.5    Roberts, J.P.6
  • 68
    • 33746566596 scopus 로고    scopus 로고
    • Expanding criteria for hepatocellular carcinoma: Down-staging with a view to liver transplantation - Yes
    • Yao FY. Expanding criteria for hepatocellular carcinoma: down-staging with a view to liver transplantation - yes. Semin Liv Dis. 2006;26:239-247.
    • (2006) Semin Liv Dis , vol.26 , pp. 239-247
    • Yao, F.Y.1
  • 69
    • 30444446963 scopus 로고    scopus 로고
    • A prospective study on down-staging of hepatocellular carcinoma prior to liver transplantation
    • Yao FY, Hirose R, LaBerge J, et al. A prospective study on down-staging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005; 11:1505-1514.
    • (2005) Liver Transpl , vol.11 , pp. 1505-1514
    • Yao, F.Y.1    Hirose, R.2    LaBerge, J.3
  • 70
    • 51349117878 scopus 로고    scopus 로고
    • Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis
    • Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48:819-827.
    • (2008) Hepatology , vol.48 , pp. 819-827
    • Yao, F.Y.1    Kerlan Jr., R.K.2    Hirose, R.3
  • 71
    • 77955699976 scopus 로고    scopus 로고
    • Loco-regional treatment of hepatocellular carcinoma
    • Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762-773.
    • (2010) Hepatology , vol.52 , pp. 762-773
    • Lencioni, R.1
  • 72
    • 0032857003 scopus 로고    scopus 로고
    • Local ablation therapy for hepatocellular carcinoma
    • Okada S. Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis. 1999;19:323-328.
    • (1999) Semin Liver Dis , vol.19 , pp. 323-328
    • Okada, S.1
  • 73
    • 15844414684 scopus 로고    scopus 로고
    • Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection
    • Ishii H, Okada S, Nose H, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer. 1996;77:1792-1796.
    • (1996) Cancer , vol.77 , pp. 1792-1796
    • Ishii, H.1    Okada, S.2    Nose, H.3
  • 74
    • 0038714350 scopus 로고    scopus 로고
    • Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection
    • Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235-240.
    • (2003) Radiology , vol.228 , pp. 235-240
    • Lencioni, R.A.1    Allgaier, H.P.2    Cioni, D.3
  • 75
    • 0032975767 scopus 로고    scopus 로고
    • Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection
    • Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210:655-661.
    • (1999) Radiology , vol.210 , pp. 655-661
    • Livraghi, T.1    Goldberg, S.N.2    Lazzaroni, S.3    Meloni, F.4    Solbiati, L.5    Gazelle, G.S.6
  • 76
    • 61949290827 scopus 로고    scopus 로고
    • Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies
    • Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453-459.
    • (2009) Hepatology , vol.49 , pp. 453-459
    • Cho, Y.K.1    Kim, J.K.2    Kim, M.Y.3    Rhim, H.4    Han, J.K.5
  • 77
    • 9644265250 scopus 로고    scopus 로고
    • Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm
    • Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology. 2004;127:1714-1723.
    • (2004) Gastroenterology , vol.127 , pp. 1714-1723
    • Lin, S.M.1    Lin, C.J.2    Lin, C.C.3    Hsu, C.W.4    Chen, Y.C.5
  • 78
    • 22344454922 scopus 로고    scopus 로고
    • A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma
    • Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122-130.
    • (2005) Gastroenterology , vol.129 , pp. 122-130
    • Shiina, S.1    Teratani, T.2    Obi, S.3
  • 79
    • 33644662778 scopus 로고    scopus 로고
    • A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma
    • Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328.
    • (2006) Ann Surg , vol.243 , pp. 321-328
    • Chen, M.S.1    Li, J.Q.2    Zheng, Y.3
  • 80
    • 0036242424 scopus 로고    scopus 로고
    • Small hepatocellular carcinoma: Comparison of radio-frequency ablation and percutaneous microwave coagulation therapy
    • Shibata T, Iimuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology. 2002;223:331-337.
    • (2002) Radiology , vol.223 , pp. 331-337
    • Shibata, T.1    Iimuro, Y.2    Yamamoto, Y.3
  • 81
    • 33645117178 scopus 로고    scopus 로고
    • Hepatocellular carcinoma: Microwave ablation with multiple straight and loop antenna clusters - Pilot comparison with pathologic findings
    • Yu NC, Lu DS, Raman SS, et al. Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters - pilot comparison with pathologic findings. Radiology. 2006;239:269-275.
    • (2006) Radiology , vol.239 , pp. 269-275
    • Yu, N.C.1    Lu, D.S.2    Raman, S.S.3
  • 82
    • 74649083955 scopus 로고    scopus 로고
    • Safety and efficacy of microwave ablation of hepatic tumors: A prospective review of a 5-year experience
    • Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010;17:171-178.
    • (2010) Ann Surg Oncol , vol.17 , pp. 171-178
    • Martin, R.C.1    Scoggins, C.R.2    McMasters, K.M.3
  • 83
    • 0037129704 scopus 로고    scopus 로고
    • Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial
    • Barcelona Liver Cancer Group
    • Llovet JM, Real MI, Montaña X, et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
    • (2002) Lancet , vol.359 , pp. 1734-1739
    • Llovet, J.M.1    Real, M.I.2    Montaña, X.3
  • 84
    • 0036085956 scopus 로고    scopus 로고
    • Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials
    • Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47-54.
    • (2002) Radiology , vol.224 , pp. 47-54
    • Cammà, C.1    Schepis, F.2    Orlando, A.3
  • 85
    • 0037308133 scopus 로고    scopus 로고
    • Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
    • Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003; 37:429-442.
    • (2003) Hepatology , vol.37 , pp. 429-442
    • Llovet, J.M.1    Bruix, J.2
  • 86
    • 67650938388 scopus 로고    scopus 로고
    • A comparative analysis of transarterial downstaging for hepatocellular carcinoma: Chemoembolization versus radioembolization
    • Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-1928.
    • (2009) Am J Transplant , vol.9 , pp. 1920-1928
    • Lewandowski, R.J.1    Kulik, L.M.2    Riaz, A.3
  • 88
    • 0030906365 scopus 로고    scopus 로고
    • Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: Interim analysis
    • Carr BI, Zajko A, Bron K, Orons P, Sammon J, Baron R. Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. Semin Oncol. 1997;24(suppl 6):97-99.
    • (1997) Semin Oncol , vol.24 , Issue.SUPPL. 6 , pp. 97-99
    • Carr, B.I.1    Zajko, A.2    Bron, K.3    Orons, P.4    Sammon, J.5    Baron, R.6
  • 89
    • 0028058678 scopus 로고
    • Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: Need for controlled trials
    • Bruix J, Castells A, Montanya X, et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology. 1994;20:643-650.
    • (1994) Hepatology , vol.20 , pp. 643-650
    • Bruix, J.1    Castells, A.2    Montanya, X.3
  • 90
    • 0026542345 scopus 로고
    • Treatment of hepatocellular carcinoma associated with advanced cirrhosis by transcatheter arterial chemoembolization using autologous blood clot: A preliminary report
    • Gunji T, Kawauchi N, Ohnishi S, et al. Treatment of hepatocellular carcinoma associated with advanced cirrhosis by transcatheter arterial chemoembolization using autologous blood clot: a preliminary report. Hepatology. 1992;15:252-257.
    • (1992) Hepatology , vol.15 , pp. 252-257
    • Gunji, T.1    Kawauchi, N.2    Ohnishi, S.3
  • 91
    • 77949264899 scopus 로고    scopus 로고
    • Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study
    • PRECISION V Investigators
    • Lammer J, Malagari K, Vogl T, et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52.
    • (2010) Cardiovasc Intervent Radiol , vol.33 , pp. 41-52
    • Lammer, J.1    Malagari, K.2    Vogl, T.3
  • 92
    • 77950810261 scopus 로고    scopus 로고
    • Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)
    • Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol. 2010;101:476-480.
    • (2010) J Surg Oncol , vol.101 , pp. 476-480
    • Dhanasekaran, R.1    Kooby, D.A.2    Staley, C.A.3    Kauh, J.S.4    Khanna, V.5    Kim, H.S.6
  • 93
    • 76649124246 scopus 로고    scopus 로고
    • Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma
    • Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21:327-332.
    • (2010) J Vasc Interv Radiol , vol.21 , pp. 327-332
    • Nicolini, A.1    Martinetti, L.2    Crespi, S.3    Maggioni, M.4    Sangiovanni, A.5
  • 94
    • 7044231876 scopus 로고    scopus 로고
    • Yttrium-90 microspheres for the treatment of hepatocellular carcinoma
    • Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127:S194-S205.
    • (2004) Gastroenterology , vol.127
    • Geschwind, J.F.1    Salem, R.2    Carr, B.I.3
  • 95
    • 33646102404 scopus 로고    scopus 로고
    • Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, and survival
    • Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-1639.
    • (2005) J Vasc Interv Radiol , vol.16 , pp. 1627-1639
    • Salem, R.1    Lewandowski, R.J.2    Atassi, B.3
  • 96
    • 33748927955 scopus 로고    scopus 로고
    • Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma
    • Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:792-800.
    • (2006) Int J Radiat Oncol Biol Phys , vol.66 , pp. 792-800
    • Sangro, B.1    Bilbao, J.I.2    Boan, J.3
  • 97
    • 74449092429 scopus 로고    scopus 로고
    • Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma
    • Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21:224-230.
    • (2010) J Vasc Interv Radiol , vol.21 , pp. 224-230
    • Kooby, D.A.1    Egnatashvili, V.2    Srinivasan, S.3
  • 98
    • 38649127852 scopus 로고    scopus 로고
    • Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis
    • Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71-81.
    • (2008) Hepatology , vol.47 , pp. 71-81
    • Kulik, L.M.1    Carr, B.I.2    Mulcahy, M.F.3
  • 99
    • 72249087123 scopus 로고    scopus 로고
    • Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: A comprehensive report of long-term outcomes
    • Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52-64.
    • (2010) Gastroenterology , vol.138 , pp. 52-64
    • Salem, R.1    Lewandowski, R.J.2    Mulcahy, M.F.3
  • 100
    • 27144557565 scopus 로고    scopus 로고
    • A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
    • Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532-1538.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 1532-1538
    • Yeo, W.1    Mok, T.S.2    Zee, B.3
  • 101
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 102
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
    • Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
    • (2009) Lancet Oncol , vol.10 , pp. 25-34
    • Cheng, A.L.1    Kang, Y.K.2    Chen, Z.3
  • 103
    • 46449091500 scopus 로고    scopus 로고
    • Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
    • Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992-2298.
    • (2008) J Clin Oncol , vol.26 , pp. 2992-12298
    • Siegel, A.B.1    Cohen, E.I.2    Ocean, A.3
  • 104
    • 33645499486 scopus 로고    scopus 로고
    • EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms
    • Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006;66:3197-3204.
    • (2006) Cancer Res , vol.66 , pp. 3197-3204
    • Pore, N.1    Jiang, Z.2    Gupta, A.3    Cerniglia, G.4    Kao, G.D.5    Maity, A.6
  • 105
    • 27244447373 scopus 로고    scopus 로고
    • Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer
    • Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23:6657-6663.
    • (2005) J Clin Oncol , vol.23 , pp. 6657-6663
    • Philip, P.A.1    Mahoney, M.R.2    Allmer, C.3
  • 106
    • 57749203825 scopus 로고    scopus 로고
    • Management of advanced hepatocellular carcinoma in the era of targeted therapy
    • Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int. 2009;29:1-7.
    • (2009) Liver Int , vol.29 , pp. 1-7
    • Yau, T.1    Chan, P.2    Epstein, R.3    Poon, R.T.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.